Armed with what CEO Robert Davis calls the “broadest and widest pipeline we’ve had in years,” Merck is preparing for its post ...

Ahead of the readouts, BMS and J&J have started an educational push called “Change the Target. Change What’s Possible,” they ...

AstraZeneca has hit what appears to be a minor speed bump in gaining clearance in the U.S. for its subcutaneous (SC) version ...

A U.K. marketing watchdog has sanctioned Sanofi after ruling its CEO Paul Hudson may have undermined the U.K. government’s ...

Thermo Fisher Scientific is continuing its recent layoff spree with a fresh round of cuts tied to a site it’s shuttering in ...

The FDA laid out the qualifications a site would need to qualify for PreCheck on a webpage where companies can also submit ...

With Valentine’s Day coming up, AbbVie has love on the brain. Ahead of the holiday, the Big Pharma has unveiled a new ...

For teams navigating an AI-driven future, this conversation offers practical clarity. Listen to the full interview to learn ...

On Friday, Eli Lilly unveiled designs on a new, $3.5 billion manufacturing facility in Pennsylvania’s Lehigh Valley, rounding ...

Shortly after acquiring Elektrofi to beef up its subcutaneous drug-delivery offerings, Halozyme Therapeutics has struck ...

Earlier this month at the J.P. Morgan Healthcare Conference, Regeneron got its Eylea sales news out of the way. | For the ...

In the latest bunch of recommendations from the European Medicines | Sanofi, Novo Nordisk, UCB and others received positive ...